VOR
Vor Biopharma Inc.Healthcare·Biotechnology
$14.97
$103M market cap
Revenue
$0.0M
Free Cash Flow
$-61.4M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for b
2-Year Price History
$14.33-46.9%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -35.1 | -35.2 | -219.6 | -38.3 | -38.3 | -0.1 | 491.5 | 2.9 | 0.4 | -835.8% | -- | -- |
| Act | 2025-Q4 | 0.0 | -35.9 | -36.0 | 1,723 | -22.8 | -23.1 | -0.3 | 455.2 | 3.0 | 9.9 | <-999% | -- | -- |
Valuation & Metrics
Market Stats
Price$14.97
Market Cap$103M
Enterprise Value$-386M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-59.9%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$1.5B
Free Cash Flow$-61.4M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-2815.2%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares5.0M
Days to Cover5.1
Change (vs Prior)+5.3%
Need at least 2 settlement dates for chart
Employees
Headcount159
Revenue / Employee$0
Gross Profit / Employee$-176
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
623.9%(+623.8% YoY)
69 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
68.7%(+68.7% YoY)
7 filers
Vanguard, iShares, SPDR
Market makers
5.6%(+5.6% YoY)
4 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| TCG Crossover Management, LLC | $96.5M | $17.84 | +$101M | +$96.5M | +4.6% | $3.50B |
| RA CAPITAL MANAGEMENT, L.P. | $96.4M | $26.15 | +$0 | +$96.4M | -4.3% | $9.44B |
| FCPM III SERVICES B.V. | $73.5M | $16.94 | +$8.9M | +$73.5M | -2.5% | $722M |
| VR Adviser, LLC | $54.3M | $20.66 | +$19.6M | +$54.3M | -1.8% | $2.68B |
| Frazier Life Sciences Management, L.P. | $45.4M | $13.08 | +$0 | +$45.4M | +2.4% | $3.89B |
| Caligan Partners LP | $34.3M | $15.55 | +$17.8M | +$34.3M | +7.0% | $1.41B |
| GREAT POINT PARTNERS LLC | $31.2M | $14.11 | +$6.8M | +$31.2M | -4.0% | $408M |
| Paradigm Biocapital Advisors LP | $31.2M | $13.08 | +$0 | +$31.2M | +2.1% | $4.69B |
| FMR LLC | $27.5M | $16.42 | −$17.6M | +$27.5M | -0.0% | $1.89T |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $25.6M | $17.84 | +$25.6M | +$25.6M | — | $4.04T |
| MARSHALL WACE, LLP | $20.6M | $17.84 | +$20.6M | +$20.6M | +0.6% | $92.71B |
| STATE STREET CORPPassive | $20.0M | $17.74 | +$18.3M | +$20.0M | -0.2% | $2.89T |
| NEXTBio Capital Management LP | $17.8M | $13.08 | +$0 | +$17.8M | +17.0% | $215M |
| BlackRock, Inc.Passive | $14.2M | $16.60 | +$5.9M | +$14.2M | -0.2% | $5.69T |
| Logos Global Management LP | $13.4M | $17.21 | +$11.6M | +$13.4M | -1.6% | $1.94B |
| Rosalind Advisors, Inc. | $12.5M | $17.84 | +$12.5M | +$12.5M | +1.1% | $244M |
| BOOTHBAY FUND MANAGEMENT, LLC | $9.9M | $17.84 | +$9.9M | +$9.9M | -0.4% | $4.25B |
| UBS Group AG | $8.7M | $20.53 | +$3.5M | +$8.7M | -0.3% | $562.11B |
| BRAIDWELL LP | $8.3M | $17.84 | +$8.3M | +$8.3M | -1.8% | $2.63B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $6.1M | $18.11 | +$2.8M | +$6.1M | +2.3% | $1.61T |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
+0.37%
avg per quarter
Holders (ex-self)
+0.39%
excl. this stock
Buyers (this Q)
+1.35%
60 buyers · $0.36B in
Sellers (this Q)
+0.37%
9 sellers · $0.01B out
alpha coverage: 96% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+74.8%
how holders react when this stock falls
On quiet Qs
-3.0%
−10% to +10% baseline
On rallies (+10%+)
+2.6%
how they react when this stock rises
Holders' portfolio flow this Q
+2.7%
inflows — adds are organic
Sellers' portfolio flow this Q
-1.8%
Sellers shed AUM broadly — partly forced.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
+0.7%
Holder mid (any stock)
-3.0%
Holder rally (any stock)
-1.7%
Biggest decreases this quarter
FMR LLC−$17.6Mα-0.0FINDELL CAPITAL MANAGEMENT LLCexited−$3.0MAMERIPRISE FINANCIAL INCexited−$2.1MSPHERA FUNDS MANAGEMENT LTD.−$1.6Mα-9.8OMERS ADMINISTRATION Corpexited−$271KXTX Topco Ltdexited−$229KPersistent Asset Partners Ltdexited−$141KShay Capital LLCexited−$141KSusquehanna Portfolio Strategies, LLCexited−$134KChung Wu Investment Group, LLCexited−$109K
New buyers this quarter
Top-5 holders · 51.1%
TCG Crossover Management, LLC--
RA CAPITAL MANAGEMENT, L.P.--
FCPM III SERVICES B.V.--
VR Adviser, LLC--
Frazier Life Sciences Management, L.P.--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
RA CAPITAL MANAGEMENT, L.P.5.4MTCG Crossover Management, LLC5.7MFCPM III SERVICES B.V.4.1MVR Adviser, LLC3.0MFrazier Life Sciences Management, L.P.2.5MCaligan Partners LP1.9MFMR LLC1.5MGREAT POINT PARTNERS LLC1.8MParadigm Biocapital Advisors LP1.8MMARSHALL WACE, LLP1.2MNEXTBio Capital Management LP1000K
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
| Ticker | Name | Co-holders | Score |
|---|---|---|---|
| SVRA | Savara Inc. | 4 | 231.71× |
| IVA | Inventiva S.A. | 3 | 157.98× |
| DYN | Dyne Therapeutics, Inc. | 4 | 154.47× |
| KALV | KalVista Pharmaceuticals, Inc. | 3 | 133.68× |
| MAZE | Maze Therapeutics, Inc. | 3 | 102.22× |
| VRDN | Viridian Therapeutics, Inc. | 3 | 102.22× |
| SYRE | Spyre Therapeutics, Inc. | 3 | 102.22× |
| PCVX | Vaxcyte, Inc. | 3 | 72.41× |
| COGT | Cogent Biosciences, Inc. | 3 | 52.66× |
| RVMD | Revolution Medicines, Inc. | 3 | 32.18× |
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (2 analysts)$24.506370.0%
Last Year (7 analysts)$38.8615960.0%
Current Price$14.97
Analyst Ratings
10
3
Buy: 10Hold: 3Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Major holders (≥10% beneficial owners)
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$110.81M
51 txns · 2 insiders · 10,870,595 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-04-22 | SELL | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 165,150 | $15.77 | $2.60M | $37.88M |
| 2026-04-20 | SELL | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 171,963 | $15.77 | $2.71M | $40.49M |
| 2026-04-17 | SELL | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 458,411 | $16.28 | $7.46M | $44.59M |
| 2026-04-15 | SELL | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 53,644 | $16.01 | $859K | $51.19M |
| 2026-04-14 | SELL | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 153,735 | $15.97 | $2.46M | $51.92M |
| 2026-04-13 | SELL | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 530,610 | $16.15 | $8.57M | $54.99M |
| 2026-04-10 | SELL | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 828 | $15.75 | $13K | $61.99M |
| 2026-04-09 | SELL | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 135,201 | $16.59 | $2.24M | $65.31M |
| 2026-04-08 | SELL | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 484,104 | $16.48 | $7.98M | $67.10M |
| 2026-04-06 | SELL | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 589,257 | $16.59 | $9.78M | $75.60M |
| 2026-04-02 | SELL | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 260,000 | $18.23 | $4.74M | $93.82M |
| 2025-10-30 | SELL | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 24,579 | $25.12 | $617K | $19.58M |
| 2025-10-29 | SELL | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 251,518 | $25.22 | $6.34M | $20.28M |
| 2025-10-28 | SELL | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 124,311 | $27.42 | $3.41M | $28.95M |
| 2025-10-27 | SELL | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 90,941 | $28.12 | $2.56M | $33.18M |
| 2025-10-24 | SELL | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 53,345 | $28.01 | $1.49M | $35.60M |
| 2025-10-23 | SELL | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 76,880 | $28.01 | $2.15M | $37.09M |
| 2025-10-21 | SELL | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 25,027 | $28.11 | $704K | $39.39M |
| 2025-10-21 | SELL | Reprogrammed Interchange LLC | 10 percent owner | 200 | $30.07 | $6K | $35.09M |
| 2025-10-20 | SELL | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 92,023 | $29.67 | $2.73M | $0 |
Order Flow (FINRA, ~3w lag)
21.0%retail-2.1pp
18.7%dark-0.7pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
VOR Biopharma: Desperate 99 Percent Workforce Liquidation and Billion-Dollar Warrant Volatility
Overall Risk
9/10
Fraud
3/10
Dilution
10/10
Insolvency
6/10
Earnings Overstated
2/10
Hidden Liabilities
9/10
Legal
4/10
Audit Warnings
7/10
Hidden Upside
4/10
Contextually Acceptable
2/10